title: [Therapeutic efficacy of three-dimensional conformal radiation therapy for patients with locally advanced non-small cell lung cancer].
abstract: OBJECTIVE
  To compare the treatment results of three-dimensional conformal radiotherapy (3D-CRT) and conventional radiotherapy (2D) for patients with locally advanced non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Five hundred and twenty seven patients with stage III NSCLC treated between Jan 2000 and Dec 2006 were included in this study. Among them, 253 cases were treated with 3D-CRT, and 274 with conventional radiotherapy. In the 3D group, 159 (62.8%) patients received chemoradiotherapy, 77 with total radiotherapy dose of > 60 Gy, 49 with 50 - 60 Gy. In the 2D group, 127 (46.4%) patients received chemoradiotherapy, 48 with total radiotherapy dose of > 60 Gy, 75 with 50 - 60 Gy.
  
  
  RESULTS
  The 1-, 3-, 5-year overall survival rates (OS) and median survival time for patients treated with 3D-CRT were 73.3%, 26.1%, 14.4% and 20.1 months, respectively, and that of patients treated with 2D radiotherapy were 61.0%, 13.8%, 8.0% and 15.6 months, respectively (P = 0.002). The 1-, 3-, 5-year cause-specific survival rates (CSS) were 79.0%, 33.3%, and 20.8% for the 3D group and 65.1%, 16.7%, 11.2%, respectively, for the 2D group (P = 0.000). The 1-, 3-, and 5-year locoregional control rates were 71.6%, 34.3% and 31.0% for patients treated with 3D radiotherapy and 57.3%, 22.1% and 19.2%, respectively, for patients treated with 2D treatment (P = 0.002). The results of multivariate analysis showed that 3D-CRT, KPS, clinical tumor response and pretreatment hemoglobin level were independently associated with increased OS and CSS. No statistically significant differences were found between the radiation complications in the two groups.
  
  
  CONCLUSIONS
  The results of our study demonstrate that 3D-conformal radiotherapy improves the survival rate in patients with stage III NSCLC compared with that of 2D radiation therapy.
authors.affiliation: Department of Radiation Oncology, Chinese Academy of Medical Sciences, Beijing, China.
authors.forename: Jian-zhong
authors.initials: JZ
authors.lastname: Cao
authors.forename: Guang-fei
authors.initials: GF
authors.lastname: Ou
authors.forename: Jun
authors.initials: J
authors.lastname: Liang
authors.forename: Ji-ma
authors.initials: JM
authors.lastname: Lü
authors.forename: Zong-mei
authors.initials: ZM
authors.lastname: Zhou
authors.forename: Dong-fu
authors.initials: DF
authors.lastname: Chen
authors.forename: Ze-fen
authors.initials: ZF
authors.lastname: Xiao
authors.forename: Qin-fu
authors.initials: QF
authors.lastname: Feng
authors.forename: Hong-xing
authors.initials: HX
authors.lastname: Zhang
authors.forename: Lü-hua
authors.initials: LH
authors.lastname: Wang
authors.forename: Wei-bo
authors.initials: WB
authors.lastname: Yin
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D059248:Chemoradiotherapy; D005260:Female; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D009367:Neoplasm Staging; D017564:Radiation Pneumonitis / Q000209:etiology; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal / Q000009:adverse effects / Q000379:methods*; D015996:Survival Rate
chemical_list: D006454:Hemoglobins